Table 4.

Risk factors for kidney disease progression in RASI group of SLE patients with aPLN.

Risk FactorsOR (95% CI)pHR (95% CI)p
Age1.01 (0.90–1.14)0.8451.01 (0.91–1.12)0.878
ISN/RPS class III or IV, LN0.55 (0.04–6.89)0.6440.32 (0.03–3.58)0.358
Acute aPLN7.2 (0.58–90.5)0.1246.71 (0.61–74.0)0.120
Baseline eGFR, for each 10-ml/min/1.73m2 increase0.56 (0.29–1.09)0.0880.62 (0.36–1.05)0.073
Baseline proteinuria, for each 1.0-g/day increase1.28 (0.99–1.66)0.0571.20 (1.00–1.45)0.046
Baseline MAP, for each 10-mmHg increase1.53 (0.80–2.93)0.1981.43 (0.82–2.49)0.210
  • Kidney disease progression is defined as 30% decline of eGFR or ESKD without remission until the end of followup. Data in bold face are statistically significant. RASI: renin-angiotensin system inhibitor; SLE: systemic lupus erythematosus; aPLN: antiphospholipid-associated nephropathy; ISN/RPS: International Society of Nephrology/Renal Pathology Society; LN: lupus nephritis; eGFR: estimated glomerular filtration rate; MAP: mean arterial pressure; ESKD: endstage kidney disease.